Treatment of neurological diseases
AssigneeLancaster University Business Enterprises Limited
InventorChristian Hölscher
Life of this patent
Estimating the term…
Abstract
Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimers disease and Parkinsons disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.
Claims20
A glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP-1) co-agonist peptide, which consists of the amino acid sequence of:
- YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2 (SEQ. ID. No. 11) wherein X=aminoisobutyric acid, or which consists of the amino acid sequence of:
- YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKKRGY-NH2 (SEQ. ID. No. 12) wherein X=aminoisobutyric acid,
- wherein a hydrophilic moiety is covalently linked to an amino acid of said peptide or wherein said peptide is conjugated with a lipophilic substituent.
A pharmaceutically acceptable salt or solvate of a glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP-1) co-agonist peptide which consists of the amino acid sequence of:
- (SEQ. ID. No. 11)
- YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2
- wherein X=aminoisobutyric acid, or which consists of the amino acid sequence of:
- (SEQ. ID. No. 12)
- YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKK
- RGY-NH2
- wherein X=aminoisobutyric acid.
A method for treatment and/or prevention of the progression of a neurological disorder selected from the group consisting of Alzheimers Disease and Parkinsons disease in a subject in need thereof, comprising administering to the subject a glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP-1) co-agonist peptide, which consists of the amino acid sequence of:
- (SEQ. ID. No. 11)
- YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKKKKKK-NH2
- wherein X=aminoisobutyric acid, or
- which consists of the amino acid sequence of:
- (SEQ. ID. No. 12)
- YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPSKRRQRRKK
- RGY-NH2
- wherein X=aminoisobutyric acid, or
- a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.